1027407-75-5

Usage

Uses

Given the provided materials, the specific uses of (Z)-1-acetyl-3-(ethoxy-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester are not explicitly stated. However, based on its structural features and the general properties of similar compounds, we can infer potential applications:
Used in Organic Synthesis:
(Z)-1-acetyl-3-(ethoxy-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester is used as a synthetic intermediate for the preparation of various organic compounds due to its reactive functional groups and structural diversity.
Used in Medicinal Chemistry:
In the pharmaceutical industry, (Z)-1-acetyl-3-(ethoxy-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester may be used as a lead compound for drug discovery, given its complex structure that could potentially interact with biological targets, such as enzymes or receptors, relevant to therapeutic applications.
Used in Chemical Research:
As a novel compound, (Z)-1-acetyl-3-(ethoxy-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester is likely to be used in academic and industrial research settings to explore its chemical properties, reactivity, and potential as a precursor to other valuable compounds.

Upstream product

• 14192-26-8 2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester 
• 121-92-6 3-nitrobenzoic acid 
• 108-24-7 acetic anhydride 
• 1663-61-2 triethoxymethylbenzene 
• 618-95-1 methyl 3-nitrobenzoate 
• 334952-07-7 4-methoxycarbonylmethyl-3-nitrobenzoic acid methyl ester 
• 676326-36-6 1-acetyl-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester 

Downstream Products

• 894783-71-2 BIBF 1202 
• 656247-17-5 nintedanib 

Relevant academic research and scientific papers

INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE

The present disclosure relates to indolinone compounds, compositions, and methods for the inhibition of maternal embryonic leucine zipper kinase (MELK). The present disclosure further relates to indolinone compounds, compositions, and methods for the treatment or prevention of a cancer (for example, triple negative breast cancer).

Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth

Despite recent advances in molecularly directed therapy, triple negative breast cancer (TNBC) remains one of the most aggressive forms of breast cancer, still without a suitable target for specific inhibitors. Maternal embryonic leucine zipper kinase (MELK) is highly expressed in TNBC, where level of overexpression correlates with poor prognosis and an aggressive disease course. Herein, we describe the discovery through targeted kinase inhibitor library screening, and structure-guided design of a series of ATP-competitive indolinone derivatives with subnanomolar inhibition constants towards MELK. The most potent compound, 17, inhibits the expression of the anti-apoptotic protein Mcl-1 and proliferation of TNBC cells exhibiting selectivity for cells expressing high levels of MELK. These studies suggest that further elaboration of 17 will furnish MELK-selective inhibitors with potential for development in preclinical models of TNBC and other cancers.

OXINDOLE INHIBITORS OF TYROSINE KINASE

The present invention relates to new oxindole inhibitors of tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.

Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor i (TGFβRI)

Inhibition of transforming growth factor β (TGFβ) type I receptor (Alk5) offers a novel approach for the treatment of fibrotic diseases and cancer. Indolinones substituted in position 6 were identified as a new chemotype inhibiting TGFβRI concomitant with